{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:39:38Z","timestamp":1787582378052,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006342","name":"Association Vaincre la Mucoviscidose","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jcf.2025.11.008","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T07:50:45Z","timestamp":1763625045000},"page":"305-313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["CFTR correctors potentiate gating mutants causing cystic fibrosis"],"prefix":"10.1016","volume":"25","author":[{"given":"Sol\u00e8ne","family":"Castanier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5356-2440","authenticated-orcid":false,"given":"Ahmad","family":"Elbahnsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Berri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1526-7013","authenticated-orcid":false,"given":"Madara","family":"Dias Wickramanayaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Mornon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Hatton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Sermet-Gaudelus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Edelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3124-887X","authenticated-orcid":false,"given":"Isabelle","family":"Callebaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6920-7761","authenticated-orcid":false,"given":"Alexandre","family":"Hinzpeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2025.11.008_bib0001","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-med-042921-021447","article-title":"Cystic fibrosis modulator therapies","volume":"74","author":"Jia","year":"2023","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jcf.2025.11.008_bib0002","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2025.11.008_bib0003","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/164_2022_597","article-title":"CFTR modulators: from mechanism to targeted therapeutics","volume":"283","author":"Yeh","year":"2024","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.jcf.2025.11.008_bib0004","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.11.008_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2024.168591","article-title":"The folding pathway of ABC transporter CFTR: effective and robust","volume":"436","author":"van der Sluijs","year":"2024","journal-title":"J Mol Biol"},{"key":"10.1016\/j.jcf.2025.11.008_bib0006","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1152\/physrev.00007.2018","article-title":"Structure, gating, and regulation of the CFTR anion channel","volume":"99","author":"Csan\u00e1dy","year":"2019","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jcf.2025.11.008_bib0007","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1085\/jgp.201711946","article-title":"Structural mechanisms of CFTR function and dysfunction","volume":"150","author":"Hwang","year":"2018","journal-title":"J Gen Physiol"},{"key":"10.1016\/j.jcf.2025.11.008_bib0008","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2016.11.014","article-title":"Atomic structure of the Cystic Fibrosis transmembrane conductance regulator","volume":"167","author":"Zhang","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jcf.2025.11.008_bib0009","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.aaw7611","article-title":"Structural identification of a hotspot on CFTR for potentiation","volume":"364","author":"Liu","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jcf.2025.11.008_bib0010","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1085\/jgp.201912360","article-title":"Identifying the molecular target sites for CFTR potentiators GLPG1837 and VX-770","volume":"151","author":"Yeh","year":"2019","journal-title":"J Gen Physiol"},{"key":"10.1016\/j.jcf.2025.11.008_bib0011","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1073\/pnas.1215982110","article-title":"Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle","volume":"110","author":"Jih","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcf.2025.11.008_bib0012","doi-asserted-by":"crossref","first-page":"36639","DOI":"10.1074\/jbc.M112.393637","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner","volume":"287","author":"Eckford","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jcf.2025.11.008_bib0013","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1038\/s41598-018-22959-6","article-title":"Sites associated with Kalydeco binding on human Cystic Fibrosis transmembrane conductance regulator revealed by Hydrogen\/Deuterium Exchange","volume":"8","author":"Byrnes","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2025.11.008_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102542","article-title":"Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator","volume":"24","author":"Laselva","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.jcf.2025.11.008_bib0015","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1126\/science.ade2216","article-title":"Molecular structures reveal synergistic rescue of \u0394508 CFTR by Trikafta modulators","volume":"378","author":"Fiedorczuk","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jcf.2025.11.008_bib0016","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2021.12.009","article-title":"Mechanism of CFTR correction by type I folding correctors","volume":"185","author":"Fiedorczuk","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jcf.2025.11.008_bib0017","doi-asserted-by":"crossref","first-page":"7813","DOI":"10.1007\/s00018-021-03994-5","article-title":"Pharmacological chaperones improve intra-domain stability and inter-domain assembly via distinct binding sites to rescue misfolded CFTR","volume":"78","author":"Baatallah","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jcf.2025.11.008_bib0018","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/mol.117.108373","article-title":"Direct binding of the corrector VX-809 to human CFTR NBD1: evidence of an allosteric coupling between the binding site and the NBD1:CL4 interface","volume":"92","author":"Hudson","year":"2017","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jcf.2025.11.008_bib0019","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI insight"},{"key":"10.1016\/j.jcf.2025.11.008_bib0020","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02774-2020","article-title":"Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator","volume":"57","author":"Laselva","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2025.11.008_bib0021","article-title":"Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment","volume":"11","author":"Shaughnessy","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2025.11.008_bib0022","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jcf.2021.03.011","article-title":"Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR","volume":"20","author":"Veit","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.11.008_bib0023","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2025.11.008_bib0024","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcf.2025.11.008_bib0025","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0014-5793(99)00647-X","article-title":"Structure-function analysis of a double-mutant cystic fibrosis transmembrane conductance regulator protein occurring in disorders related to cystic fibrosis","volume":"452","author":"Fanen","year":"1999","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jcf.2025.11.008_bib0026","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/ijms232416225","article-title":"Acting on the CFTR membrane-spanning domains interface rescues some misfolded mutants","volume":"23","author":"Baatallah","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2025.11.008_bib0027","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00018-024-05431-9","article-title":"Novel gain-of-function mutants identify a critical region within CFTR membrane-spanning domain 2 controlling cAMP-dependent and ATP-independent channel activation","volume":"81","author":"Castanier","year":"2024","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jcf.2025.11.008_bib0028","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera\u2013a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J Comput Chem"},{"key":"10.1016\/j.jcf.2025.11.008_bib0029","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00018-022-04671-x","article-title":"ABC-transporter CFTR folds with high fidelity through a modular, stepwise pathway","volume":"80","author":"Im","year":"2023","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jcf.2025.11.008_bib0030","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.1038\/s41598-023-34440-0","article-title":"Novel tricyclic pyrrolo-quinolines as pharmacological correctors of the mutant CFTR chloride channel","volume":"13","author":"Renda","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2025.11.008_bib0031","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s00018-004-4422-3","article-title":"Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains","volume":"62","author":"Moran","year":"2005","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jcf.2025.11.008_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112116","article-title":"Targeting different binding sites in the CFTR structures allows to synergistically potentiate channel activity","volume":"190","author":"Froux","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jcf.2025.11.008_bib0033","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jcf.2019.10.011","article-title":"Mutation-specific dual potentiators maximize rescue of CFTR gating mutants","volume":"19","author":"Veit","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.11.008_bib0034","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.chembiol.2014.02.021","article-title":"VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface","volume":"21","author":"Eckford","year":"2014","journal-title":"Chem Biol"},{"key":"10.1016\/j.jcf.2025.11.008_bib0035","doi-asserted-by":"crossref","first-page":"15215","DOI":"10.1074\/jbc.M110.184267","article-title":"Dual activity of aminoarylthiazoles on the trafficking and gating defects of the cystic fibrosis transmembrane conductance regulator chloride channel caused by cystic fibrosis mutations","volume":"286","author":"Pedemonte","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jcf.2025.11.008_bib0036","doi-asserted-by":"crossref","first-page":"eadk1814","DOI":"10.1126\/sciadv.adk1814","article-title":"A uniquely efficacious type of CFTR corrector with complementary mode of action","volume":"10","author":"Marchesin","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.jcf.2025.11.008_bib0037","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1038\/s41467-024-50641-1","article-title":"Allosteric inhibition of CFTR gating by CFTRinh-172 binding in the pore","volume":"15","author":"Gao","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcf.2025.11.008_bib0038","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2316675121","article-title":"Structural basis for CFTR inhibition by CFTR(inh)-172","volume":"121","author":"Young","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcf.2025.11.008_bib0039","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jcf.2022.12.005","article-title":"Rescue by elexacaftor-tezacaftor-ivacaftor of the G1244E cystic fibrosis mutation's stability and gating defects are dependent on cell background","volume":"22","author":"Tomati","year":"2023","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325025044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325025044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:36:43Z","timestamp":1781782603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325025044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1569199325025044"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.11.008","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CFTR correctors potentiate gating mutants causing cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}